Orphazyme upgrades after careful spending year

Several reporting parameters have been adjusted upward by biotech firm Orphazyme, which has fared better than feared in 2021.

Photo: Orphazyme/PR

Orphazyme tightened its belt in 2021, resulting in lower-than-expected costs for the year. Now, the biotech company is upgrading its 2021 financial forecast a few months prior to the report's full release, a press release announced on Tuesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs